Gregory Piazza Presents HI-PRO Trial Results on VTE at ESC Congress
Gregory Piazza, Director of the Vascular Medicine Section at Brigham and Women’s Hospital, posted on LinkedIn:
‘‘Venous thromboembolism (VTE) has traditionally been categorized as unprovoked and treated with extended anticoagulation or provoked and prescribed time-limited anticoagulation for 3 months.
What do we do with patients who have provoked events but other persistent risk factors like obesity or heart disease?
We answered this question in the HI-PRO randomized controlled trial presented in Madrid at the European Society of Cardiology Congress and simultaneously published in the New England Journal of Medicine.
The culmination of 5 years of blood, sweat, and almost tears, it would not have been possible without an amazing team, my co-investigators and the Thrombosis Research Group team!”
Watch the full video here.
Read the full article in NEJM.
Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism
Authors: Gregory Piazza, Behnood Bikdeli, Arvind Pandey, Darsiya Krishnathasan, Candrika Khairani, Antoine Bejjani, Ruth Morrison, Heather Hogan, Sina Rashedi, Mariana Pfeferman, Junyang Lou, John Fanikos, Nicole Porio, Lisa Rosenbaum, Piotr Sobieszczyk, Zhou Lan, Marie Gerhard-Herman, Umberto Campia, Samuel Goldhaber
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Dec 18, 2025, 17:13Daria Camilli on EuroBloodNet and EHC Collaboration for Bleeding Disorders
-
Dec 18, 2025, 16:50Marie Cambot on Innovhem’s Quantification of The HbF/HbS Ratio for SCD
-
Dec 18, 2025, 16:26Yogesh Rathod on Hematological Issues and ICU
-
Dec 18, 2025, 16:09Carlos Doti: I’m Reminded Why ASH is Such a Powerful Close to The Year
-
Dec 18, 2025, 15:23Michael Hadley: Well-Timed ACC Statement Just Out in JACC Journals
-
Dec 18, 2025, 15:12Wolfgang Miesbach on Insights from Guy Young’s ASH2025 Session on Next-Generation Gene Therapy
-
Dec 18, 2025, 14:15Plasma-Derived Therapy for Hemophilia in The Updated European Medicines Agency’s Union List
-
Dec 18, 2025, 13:55Laurent Bertoletti: BAT-VTE is One of 7 Projects Funded Under the EFFECT Trial Call!
-
Dec 18, 2025, 13:34Alexandru Stieber Explores VEXAS Syndrome